Business Context and Reporting Period
This Form 8-K is filed by Heatwurx, Inc. (not Processa Pharmaceuticals, Inc.) for the reporting period ending January 15, 2014. The filing discloses recent debt financing activities, unregistered sales of equity securities, and director compensation arrangements.
Key Financial Metrics and Capital Activities
- Debt Financing: Issued two promissory notes totaling $100,000 ($50,000 each) on January 15, 2014, under a Loan Agreement dated January 6, 2014.
- Equity Financing: Received $99,996 from an initial investor in a private offering of Series D Preferred Stock units.
- Securities Issued:
- 16,667 warrants issued to each of two debt investors (33,334 total) in connection with the $100,000 notes.
- Units consisting of Series D Preferred Stock and warrants sold to an initial equity investor.
- Compensation Expense: Granted options to purchase 10,000 shares of Common Stock to each director for 2013 services.
- Transaction Costs: Paid $5,999.76 in selling commissions for the equity offering.
Material Changes and Transaction Details
- Debt Structure: The $100,000 in notes were issued alongside warrants as part of a broader $1,000,000 debt financing facility.
- Equity Offering Terms:
- Offering size: Up to 772,352 units at $3.00 per unit.
- Unit composition: One share of Series D Preferred Stock and one-half warrant.
- Warrant exercise price: $3.00 per share.
- Conversion: Series D Shares convert to common stock at the holder's option or automatically if the common stock trades at or above $4.50 per share for ten consecutive trading days.
- Director Options: Options granted on January 16, 2014, are fully vested, exercisable at $3.00 per share, and expire in five years.
Guidance, Risks, and Contingencies
- Registration Status: All securities sold (notes, warrants, and units) were issued without registration under the Securities Act, relying on exemptions under Section 4(a)(2), Section 4(a)(5), and Rule 506(b).
- Investor Eligibility: Sales were made exclusively to "accredited investors" or sophisticated investors meeting specific suitability standards.
- Future Obligations: The Company agreed to use reasonable best efforts to file a registration statement within 90 days following the completion of the offering to register common shares issuable upon warrant exercise.
- Liquidity Context: The filing indicates active capital raising efforts to secure working capital through both debt and equity instruments.
Key Facts for Investor Verification
- Verify the total outstanding debt under the January 6, 2014 Loan Agreement, as this filing only covers the $100,000 tranche issued on January 15.
- Confirm the total number of units sold in the Series D Preferred Stock offering to date, as only the initial $99,996 transaction is reported here.
- Monitor the Company's ability to file the required registration statement for warrant-exercisable shares within the 90-day window.
- Review the full terms of the Series D Preferred Stock conversion adjustments and any potential dilution impacts.